DVAX Key Statistics, Chart & Performance
The current stock price of DVAX is 15.5 USD. In the past month the price increased by 0.58%. In the past year, price increased by 17.87%.
DVAX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DVAX. When comparing the yearly performance of all stocks, DVAX is one of the better performing stocks in the market, outperforming 86.4% of all stocks.
DVAX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DVAX. Both the profitability and the financial health of DVAX get a neutral evaluation. Nothing too spectacular is happening here.
DVAX Financial Highlights
Over the last trailing twelve months DVAX reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 211.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.59% | ||
| ROE | -8.13% | ||
| Debt/Equity | 0.49 |
DVAX Forecast & Estimates
9 analysts have analysed DVAX and the average price target is 24.48 USD. This implies a price increase of 57.94% is expected in the next year compared to the current price of 15.5.
For the next year, analysts expect an EPS growth of -318.17% and a revenue growth 21.89% for DVAX
DVAX Ownership
DVAX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DVAX
Company Profile
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 405 full-time employees. The company went IPO on 2004-02-19. The firm has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The firm is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Company Info
DYNAVAX TECHNOLOGIES CORP
2100 Powell Street, Suite 720
Emeryville CALIFORNIA 94608 US
CEO: Ryan Spencer
Employees: 405
Phone: 15108485100
DYNAVAX TECHNOLOGIES CORP / DVAX FAQ
What does DVAX do?
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 405 full-time employees. The company went IPO on 2004-02-19. The firm has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The firm is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Can you provide the latest stock price for DYNAVAX TECHNOLOGIES CORP?
The current stock price of DVAX is 15.5 USD. The price increased by 0.06% in the last trading session.
Does DYNAVAX TECHNOLOGIES CORP pay dividends?
DVAX does not pay a dividend.
What is the ChartMill technical and fundamental rating of DVAX stock?
DVAX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What is the analyst forecast for DVAX stock?
9 analysts have analysed DVAX and the average price target is 24.48 USD. This implies a price increase of 57.94% is expected in the next year compared to the current price of 15.5.
What is the expected growth for DVAX stock?
The Revenue of DYNAVAX TECHNOLOGIES CORP (DVAX) is expected to grow by 21.89% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for DVAX stock?
DYNAVAX TECHNOLOGIES CORP (DVAX) will report earnings on 2026-02-18, after the market close.